Hearing loss in patients on treatment for drug-resistant tuberculosis

European Respiratory Journal

Volumn 40, Issue 5, 2012, Pages 1277-1286

  Seddon, James A ^a,d   Godfrey Faussett, Peter ^d   Jacobs, Kayleen ^c   Ebrahim, Adam ^c   Hesseling, Anneke C ^a   Schaaf, H Simon ^a,b  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c Brooklyn Chest Hospital   (South Africa)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Drug resistant; Hearing loss; Ototoxicity; Systematic review; Tuberculosis

Indexed keywords

AMIKACIN; CAPREOMYCIN; KANAMYCIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

AUDIOMETRY; CHEMOTHERAPY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG MONITORING; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; DRUG USE; GENETIC ASSOCIATION; HEARING; HEARING IMPAIRMENT; HEARING TEST; HUMAN; KIDNEY FAILURE; NONHUMAN; OTOSCOPY; OTOTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STANDARDIZATION; TYMPANOMETRY;

ANTITUBERCULAR AGENTS; HEARING LOSS; HEARING TESTS; HUMANS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84868576422     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00044812     Document Type: Review

References (76)

1. World Health Organization. Global Tuberculosis Control: WHO Report 2011. WHO/HTM/TB/2011.16 2011. Geneva, WHO, 2011.
2. World Health Organization. Molecular Line Probe Assays for the rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Policy Statement. Geneva, WHO, 2008. www. who.int/tb/features-archive/policy- statement.pdf
3. World Health Organization. Roadmap for rolling out Xpert MTB/RIF for rapid diagnosis of TB and MDR-TB. Geneva, WHO, 2010. www. who.int/tb/laboratory/ roadmap-xpert-mtb-rif-rev23dec2010.pdf
4. World Health Organization. Guidlelines for the programmatic management of drug-resistant tuberculosis. Emergency update. WHO/HTM/TB/2008.402. Geneva, WHO, 2008.
5. Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des 2007; 13: 119-126.
6. Guthrie OW. Aminoglycoside induced ototoxicity. Toxicology 2008; 249: 91-96.
7. Torres-Russotto D, Landau WM, Harding GW, et al. Calibrated finger rub auditory screening test (CALFRAST). Neurology 2009; 72: 1595-1600.
8. Bess FH, Dodd-Murphy J, Parker RA. Children with minimal sensorineural hearing loss: prevalence, educational performance, and functional status. Ear Hear 1998; 19: 339-354.
9. Eisenberg LS. Current state of knowledge: speech recognition and production in children with hearing impairment. Ear Hear 2007; 28: 766-772.
10. Jerger S. Current state of knowledge: perceptual processing by children with hearing impairment. Ear Hear 2007; 28: 754-765.
11. Livingstone N, McPhillips M. Motor skill deficits in children with partial hearing. Dev Med Child Neurol 2011; 53: 836-842.
12. Moeller MP. Current state of knowledge: psychosocial development in children with hearing impairment. Ear Hear 2007; 28: 729-739.
13. Moeller MP, Tomblin JB, Yoshinaga-Itano C, et al. Current state of knowledge: language and literacy of children with hearing impairment. Ear Hear 2007; 28: 740-753.
14. Stelmachowicz PG, Pittman AL, Hoover BM, et al. The importance of high-frequency audibility in the speech and language development of children with hearing loss. Arch Otolaryngol Head Neck Surg 2004; 130: 556-562.
15. Yoshinaga-Itano C, Sedey AL, Coulter DK, et al. Language of early-and later-identified children with hearing loss. Pediatrics 1998; 102: 1161-1171.
16. Moeller MP. Early intervention and language development in children who are deaf and hard of hearing. Pediatrics 2000; 106: E43.
17. British Society of Audiology. Pure tone air and bone conduction threshold audiometry with and without masking and determination of uncomfortable loudness levels. Reading, British Society of Audiology, 2004. www.thebsa.org.uk/docs/ RecPro/PTA.pdf
18. Goodman A. Reference zero levels for pure tone audiometer. ASHA 1965; 7: 262-263.
19. Katz J, Medwetsky L, Burkard R, et al. Handbook of Clinical Audiology. 6th Edn. Baltimore, Lippincott Williams and Wilkins, 2009.
20. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
21. Johnston JC, Shahidi NC, Sadatsafavi M, et al. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009; 4: e6914.
22. de Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis 2002; 6: 622-627.
23. Duggal P, Sarkar M. Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up. BMC Ear Nose Throat Disord 2007; 7: 5.
24. Kennedy B, O'Connor B, Korn B, et al. Multi-drug resistant tuberculosis: experiences of two tertiary referral centres. Ir Med J 2011; 104: 182-185.
25. Brummett RE, Fox KE. Aminoglycoside-induced hearing loss in humans. Antimicrob Agents Chemother 1989; 33: 797-800.
26. Peloquin CA, Berning SE, Nitta AT, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 2004; 38: 1538-1544.
27. Sturdy A, Goodman A, Jose RJ, et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother 2011; 66: 1815-1820.
28. Baghaei P, Tabarsi P, Dorriz D, et al. Adverse effects of multidrug-resistant tuberculosis treatment with a standardized regimen: a report from Iran. Am J Ther 2011; 18: e29-e34.
29. Bloss E, Kuksa L, Holtz TH, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004. Int J Tuberc Lung Dis 2010; 14: 275-281.
30. Burgos M, Gonzalez LC, Paz EA, et al. Treatment of multidrug-resistant tuberculosis in San Francisco: an outpatient-based approach. Clin Infect Dis 2005; 40: 968-975.
31. Chan ED, Laurel V, Strand MJ, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169: 1103-1109.
32. Codecasa LR, Ferrara G, Ferrarese M, et al. Long-term moxiflox-acin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs. Respir Med 2006; 100: 1566-1572.
33. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010; 375: 1798-1807.
34. Drobac PC, Mukherjee JS, Joseph JK, et al. Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics 2006; 117: 2022-2029.
35. Furin JJ, Mitnick CD, Shin SS, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001; 5: 648-655.
36. Geerligs WA, Van Altena R, De Lange WCM, et al. Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands. Int J Tuberc Lung Dis 2000; 4: 758-764.
37. Goble M, Iseman MD, Madsen LA, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527-532.
38. Isaakidis P, Cox HS, Varghese B, et al. Ambulatory multi-drug resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, India. PLoS One 2011; 6: e28066.
39. Jacob V, Robert L, Lebrun C, et al. Multidrug-resistant tuberculosis: a review of the 23 cases treated by the Saint-Pierre University Hospital (Brussels). Acta Clinica Belgica 2009; 64: 113-119.
40. Joseph P, Desai VBR, Mohan NS, et al. Outcome of standardized treatment for patients with MDR-TB from Tamilnadu, India. Indian J Med Res 2011; 133: 529-534.
41. Karagöz T, Yazicioglu Moçin O, Pazarli P, et al. The treatment results of patients with multidrug resistant tuberculosis and factors affecting treatment outcome. Tuberkuloz ve Toraks 2009; 57: 383-392.
42. Keal JL, Khachi H, Hanzaree E, et al. P56 Treatment of multidrug resistant tuberculosis: where are the guidelines for monitoring? Thorax 2011; 66: A91.
43. Keshavjee S, Gelmanova IY, Farmer PE, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 2008; 372: 1403-1409.
44. Kim HR, Hwang SS, Kim HJ, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 2007; 45: 1290-1295.
45. Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318-326.
46. Malla P, Kanitz EE, Akhtar M, et al. Ambulatory-based standardized therapy for multi-drug resistant tuberculosis: experience from Nepal, 2005-2006. PLoS One 2009; 4: e8313.
47. Masjedi MR, Tabarsi P, Chitsaz E, et al. Outcome of treatment of MDR-TB patients with standardised regimens, Iran, 2002-2006. Int J Tuberc Lung Dis 2008; 12: 750-755.
48. Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 2004; 8: 1382-1384.
49. Palmero DJ, Ambroggi M, Brea A, et al. Treatment and follow-up of HIV-negative multidrug-resistant tuberculosis patients in an infectious diseases reference hospital, Buenos Aires, Argentina. Int J Tuberc Lung Dis 2004; 8: 778-784.
50. Shin SS, Pasechnikov AD, Gelmanova IY, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis 2007; 11: 1314-1320.
51. Tahaoglu K, Torun T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345: 170-174.
52. Telzak EE, Sepkowitz K, Alpert P, et al. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med 1995; 333: 907-911.
53. Törün T, Gungor G, Ozmen I, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 1373-1377.
54. Tupasi TE, Gupta R, Quelapio MI, et al. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med 2006; 3: e352.
55. Uffredi ML, Truffot-Pernot C, Dautzenberg B, et al. An intervention programme for the management of multidrug-resistant tuberculosis in France. Int J Antimicrob Agents 2007; 29: 434-439.
56. Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-692.
57. Yew WW, Chan CK, Chau CH, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with oflox-acin/levofloxacin- containing regimens. Chest 2000; 117: 744-751.
58. Partners in Health. The Partners in Health Guide to the Medical Management of Multidrug-Resistant Tuberculosis. Boston, Partners in Health, 2003.
59. Partners in Health, Harvard Medical School, Bill & Melinda Gates Foundation. A DOTS-Plus Handbook-Guide to the Community-Based Treatment of MDR TB. Boston, Partners in Health, 2004.
60. Francis J Curry National Tuberculosis Centre. Drug-Resistant Tuberculosis: A Survival Guide for Clinicians. 2nd Edn. San Francisco, Francis J.Curry National Tuberculosis Center, 2008.
61. American Speech-Language-Hearing Association. Guidelines for Audiologic Screening. Rockville, American Speech-Language-Hearing Association, 1997. www.asha.org/docs/pdf/GL1997-00199.pdf
62. American Speech-Language-Hearing Association. Audiologic Screening (Technical Report). Rockville, American Speech-Language-Hearing Association, 1994. www.asha.org/docs/pdf/TR1994-00238.pdf
63. American Speech-Language-Hearing Association. Audiologic Management of Inidividuals Receiving Cochleotoxic Drug Therapy (Guideline). Rockville, American Speech-Language-Hearing Association, 1994. www.asha.org/docs/pdf/ GL1994-00003.pdf
64. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. NIH Publication No. 09-5410. Bethesda, National Institutes of Health, 2009. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010- 06-14-Quick Reference-5x7.pdf
65. Brock PR, Bellman SC, Yeomans EC, et al. Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol 1991; 19: 295-300.
66. Chang KW, Chinosornvatana N. Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol 2010; 28: 1788-1795.
67. Durrant JD, Campbell K, Fausti S, et al. American Academy of Audiology Position Statement and Clinical Practice Guidelines. Ototoxicity Monitoring. Washington, American Academy of Audio-logy, 2009. www.audiology.org/resources/ documentlibrary/docu ments/otomonpositionguideline.pdf Date last accessed: January 26, 2012.
68. Médecins Sans Frontières. Scaling up diagnosis and treatment of drug-resistant tuberculosis in Khayelitsha, South Africa: an integrated, community-based approach. www.msfaccess.org/sites/default/files/MSF- assets/TB/Docs/TB-report-ScalingUpDxTxKha ye-ENG-2011.pdf Date last accessed: September 5, 2011.
69. Bardien S, de Jong G, Schaaf HS, et al. Aminoglycoside-induced hearing loss: South Africans at risk. S Afr Med J 2009; 99: 440-441.
70. Bardien S, Human H, Harris T, et al. A rapid method for detection of five known mutations associated with aminoglycoside-induced deafness. BMC Med Genet 2009; 10: 2.
71. Gardner JC, Goliath R, Viljoen D, et al. Familial streptomycin ototoxicity in a South African family: a mitochondrial disorder. J Med Genet 1997; 34: 904-906.
72. Human H, Hagen CM, de Jong G, et al. Investigation of mitochondrial sequence variants associated with aminoglycoside-induced ototoxicity in South African TB patients on aminoglyco-sides. Biochem Biophys Res Commun 2010; 393: 751-756.
73. Hutchin T, Haworth I, Higashi K, et al. A molecular basis for human hypersensitivity to aminoglycoside antibiotics. Nucleic Acids Res 1993; 21: 4174-4179.
74. Sha SH, Qiu JH, Schacht J. Aspirin to prevent gentamicin-induced hearing loss. N Engl J Med 2006; 354: 1856-1857.
75. Schaaf HS, Seddon JA, Caminero JA. Second-line antituberclosis drugs: current knowledge and controversies. Prog Respir Res 2011; 40: 81-95.
76. World Health Organization. Geneva, Switzerland. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update. WHO/HTM/TB/2011.6. Geneva, WHO, 2011.